Join for free and get access to the buyside
Get insights from the world's most influential hedge fund investors direct to your inbox
- © 2025 Buyside Digest
- Privacy Policy
- Disclaimer
- Sitemap
- Terms of Service
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Keywords/Themes | Theme Commentary | Pitches | Letter |
|---|---|---|---|---|---|---|---|---|---|
| 2025 Q2 | Jul 22, 2025 | Alger Weatherbie Specialized Growth Fund | 11.6% | -5.2% | ACAD, NEO, NEOG, RXO, STRL, UPST | Compounding, earnings, growth, innovation, Resilience | The letter focuses on companies with durable growth profiles benefiting from secular innovation, strong balance sheets, and expanding end markets. Management highlights disciplined stock selection amid market volatility, emphasizing earnings resilience and long-term compounding rather than short-term macro noise. Growth opportunities are framed around companies capable of sustaining above-average revenue and cash flow expansion. | NEO RXO NEOG ACAD UPST STRL |
View |
| 2024 Q1 | Apr 15, 2024 | Alger Weatherbie Specialized Growth Fund | 5.8% | 9.5% | ACAD, CWST, NTRA, NVRO, PI, XMTR | - | View | ||
| 2023 Q4 | Dec 31, 2023 | Alger Weatherbie Specialized Growth Fund | 5.8% | 9.5% | ACAD, CLB, FLYW, NTRA, STEP, VERX | - | View | ||
| 2025 Q4 | Jan 15, 2026 | Alger Weatherbie Specialized Growth Fund | 1.8% | 0.5% | ACAD, AIR, FSV, GKOS, KTOS, NTRA | AI, Biotechnology, defense, growth, healthcare, industrials, small cap, technology | The market's biggest tailwind was continued investment tied to artificial intelligence, though increasingly accompanied by scrutiny around AI infrastructure bottlenecks, sources of financing, and whether the AI theme could deliver returns commensurate with the capital deployed. AI is at an inflection point, potentially enabling significant increases in productivity. Cloud computing is growing and supporting innovation as corporations are digitizing their operations. This represents one of the secular themes creating attractive investment opportunities. Portfolio includes significant exposure to biopharmaceutical companies like Natera with genetic testing platforms, ACADIA Pharmaceuticals focused on CNS disorders, and Glaukos developing ophthalmic medical technologies. These companies are advancing novel therapies and diagnostic capabilities. Investment in Kratos Defense & Security Solutions reflects focus on affordable unmanned systems, hypersonics and rocket systems, and satellite command-and-control, which are increasingly aligned with U.S. and allied priorities around rapid fielding and scalable production. | KTOS AIR FSV GKOS ACAD NTRA |
View |
| Date | Pitch Type | Author | Company | Industry | Sub Industry | Bull / Bear | Stock Exchange | Keywords | Action |
|---|---|---|---|---|---|---|---|---|---|
| Jan 27, 2026 | Fund Letters | H. George Dai | ACADIA Pharmaceuticals Inc. | Health Care | Biotechnology | Bull | NASDAQ | Biotech, CNS, FDA, growth, Orphan_Drugs | View Pitch |
| Dec 5, 2025 | Seeking Alpha | Seeking Alpha | Acadia Pharmaceuticals Inc. | Biotechnology | Bull | ACP-204, Alzheimer's disease, CNS disorders, Daybue, financial health, Intellectual Property, international expansion, Nuplazid, pipeline strategy, R&D investment | View Pitch | ||
| Dec 3, 2025 | Fund Letters | H. George Dai | Acadia Pharmaceuticals Inc. | Health Care | Biotechnology | Bull | NASDAQ | biopharma, growth, Neurology, Prescriptions, Raredisease | View Pitch |
| Sep 16, 2025 | Short Thesis | Culper Research | ACADIA Pharmaceuticals Inc | Health Care | Biotechnology | Bear | NASDAQ | Biotech, Daybue, Nuplazid, pipeline, Reimbursement | View Pitch |
| Manager Name | Fund Name | Fund AUM | Invested Value | Portfolio Weight | Shares Owned | Shares Bought / Sold During Quarter | % Bought / Sold During Quarter | % of Shares Outstanding Owned |
|---|---|---|---|---|---|---|---|---|
| No investor data available. | ||||||||